Akebia Therapeutics, Inc.
AKBANASDAQHealthcare● Active
$0.92
$-0.01(-1.28%)
Market Cap$247682610
P/E Ratio—
52W High$4.079
52W Low$0.875
Akebia Therapeutics, Inc. (AKBA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AKBA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.24B | $0.16B | $0.19B | $0.29B | $0.21B |
| Cost of Revenue | $0.04B | $0.06B | $0.07B | $0.02B | $0.08B |
| Gross Profit | $0.20B | $0.10B | $0.12B | $0.27B | $0.13B |
| Gross Margin %(computed) | 83.29% | 60.56% | 61.90% | 92.31% | 61.50% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.04B | $0.06B | $0.17B | $0.15B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.13B | $0.17B |
| Total Operating Expenses | $0.17B | $0.15B | $0.17B | $0.35B | $0.39B |
| Operating Income | $0.02B | ($0.05B) | ($0.05B) | ($0.08B) | ($0.26B) |
| Operating Margin %(computed) | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.01B | $0.02B | $0.02B |
| Income Before Tax | ($0.00B) | ($0.07B) | ($0.05B) | ($0.09B) | ($0.28B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.07B) | ($0.05B) | ($0.09B) | ($0.28B) |
| Net Margin %(computed) | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.33 | $-0.28 | $-0.58 | $-1.48 |
| Wtd Avg Shares | 0.26B | 0.21B | 0.19B | 0.18B | 0.17B |
| EBITDA | $0.02B | ($0.01B) | ($0.01B) | $0.00B | ($0.19B) |
| EBITDA Margin %(computed) | 9.20% | -8.57% | -4.25% | 1.04% | -89.73% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Akebia Therapeutics, Inc. data
About Akebia Therapeutics, Inc. (AKBA) Income Statement
Akebia Therapeutics, Inc. (AKBA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AKBA reported revenue of $0.24B, gross profit of $0.20B (gross margin 83.29%), and net income of ($0.01B) — a net profit margin of -2.26%.
Frequently asked questions
AKBA · 4 questionsAkebia Therapeutics, Inc. (AKBA) reported revenue of $0.24B for 2025, up 47.5% year-over-year.
AKBA revenueAKBA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08